when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

92 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT829 Endpoints634 BioPharma Dive241 onclive165 Fierce Biotech93 BioSpace91 raps37 globenewswire health

therapy area

all Oncology4996 Rare Disease831 Hematology764 Cardiology717 Immunology715 Psychiatry & CNS579 Pulmonology

Early Alert: Percutaneous Catheter Issue from Boston Scientific
ENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during use
fda medwatch · 7d ago↗ source
BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION
July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter…
fda recalls · 7d ago↗ source
American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter

← prev

page 1 of 4

28

570

Endocrinology & Metabolism288

Ophthalmology254

Infectious Disease247

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consume…

fda recalls · 7d ago↗ source

Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits

Prolonged use of the Abiomed 14Fr Low Profile Introducer may lead to thrombus formation.

fda medwatch · 14d ago↗ source

Thoracic Stent Graft Recall: Bolton Medical Removes Relay Pro System

Affected grafts may not unclasp from the delivery system. This may require conversion to open surgical repair and can result in patient death.

fda medwatch · 14d ago↗ source

Early Alert: Convenience Kit Issue from Medical Action Industries

Particulates have the potential to be introduced into blood circulation and become lodged within blood vessels.

fda medwatch · 22d ago↗ source

Infusion Pump Correction: Fresenius Kabi Issues Correction for Ivenix Large Volume Infusion Pump

A software anomaly may cause a false battery-health value. The pump should remain plugged in at all times.

fda medwatch · 24d ago↗ source

Infusion Pump Correction: Fresenius Kabi Issues Correction for dropped or jarred Ivenix Large Volume Infusion Pumps

If dropped, the Ivenix pump touchscreen may become unresponsive and should be removed from use.

fda medwatch · 24d ago↗ source

Convenience Kit Correction: Windstone Medical Packaging, Inc. Issues Correction for Convenience Kit

Certain Cardinal Health Webcol Large Alcohol Prep Pads in Custom Convenience Kits manufactured by Aligned Medical Solutions are not sterile.

fda medwatch · 25d ago↗ source

Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

onclive · 2mo ago↗ source

FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML

The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.

onclive · 2mo ago↗ source

FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma

The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.

onclive · 2mo ago↗ source

Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

onclive · 2mo ago↗ source

Future Directions in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC) and…

onclive · 2mo ago↗ source

Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharmaceutical…

onclive · 2mo ago↗ source

Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant prostate…

onclive · 2mo ago↗ source

Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…

onclive · 2mo ago↗ source

Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

onclive · 2mo ago↗ source

Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…

onclive · 2mo ago↗ source

Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on the scient…

onclive · 2mo ago↗ source

Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining how these…

onclive · 2mo ago↗ source

Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors

Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.

onclive · 2mo ago↗ source

UCSF Receives Major Gift to Advance Research and Modernization

Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.

onclive · 2mo ago↗ source